Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.08 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)2.17M
Market Cap
$1.01B
Enterprise Value$2.90B
Total Cash (Recent Filing)$358.08M
Total Debt (Recent Filing)$604.78M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Jul 30, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding128,694,500
10 Day Avg. Volume1,650,905
30 Day Avg. Volume2,168,374
Financial Highlights & Ratios
PEG Ratio2.08
Price to Book (P/B)5.79
Price to Sales (P/S)0.00
P/FCF Ratio879.86
Enterprise Value/Market Cap2.87
Enterprise Value/Revenue1.11
Enterprise Value/Gross Profit9.84
Enterprise Value/Ebitda-382.50
Forecast
1Y Price Target
$13.19Price Target Upside78.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering12
NeoGenomics News
PremiumCompany Announcements
NeoGenomics Approves Key Proposals at Annual Meeting
Bulls Say, Bears Say
Bulls Say
Acquisition ImpactThe Pathline acquisition should improve turnaround times in the Northeast, enabling NEO to win new market share.
Management StrategyThe business is executing as expected, and management believes they can return to beating estimates within a couple of quarters.
Revenue GuidanceNEO raised the FY25 guidance for revenues to reflect the inclusion of additional revenue related to the acquisition of Pathline, LLC.
Bears Say
Management ChangesThe recent management changes, including the departure of the former CEO and appointment of a new CEO, raise the risk of further senior management turnover.
Market CompetitionThe NGS solid tumor CGP market is becoming more competitive, making a 25% growth expectation for 2025-26 unlikely to materialize.
Revenue OutlookThe growth outlook for NeoGenomics Inc. appears challenging with an overly aggressive guidance for 2025.
Ownership Overview
1.12% Insiders
38.04% Mutual Funds
23.24% Other Institutional Investors
12.56% Public Companies and Individual Investors
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $6.08 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.01B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Jul 30, 2025 which is in 46 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Apr 29, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.013 by $0.013.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics does not currently pay dividends.
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.03.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 128,694,500 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0 in its last earnings report, beating expectations of -$0.013. Following the earnings report the stock price went down -34.002%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
NeoGenomics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$13.19 (78.48% Upside)
$13.19 (78.48% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 131.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $434.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 10.2%
Last 30 Days ▼ 10.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.50%
12-Months-Change
Fundamentals
Return on Equity
-8.57%
Trailing 12-Months
Asset Growth
-2.37%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing services and oncology-related clinical and pharmaceutical services. The company operates in the healthcare sector, specializing in diagnostic testing services across various modalities, including cytogenetics, flow cytometry, immunohistochemistry, molecular testing, and pathology consultation. NeoGenomics serves a diverse client base, including pathologists, oncologists, hospitals, research institutions, and pharmaceutical companies, with the goal of improving patient care through precise and timely diagnostic insights.
NEO Company Deck
NEO Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with significant growth in revenue and EBITDA, expansion through acquisitions, and strong performance in clinical testing volumes and NGS revenue. However, there were challenges in the non-clinical sector, particularly in pharma and biotech spending. Despite these challenges, the company's strategic initiatives and market positioning in oncology provide a robust outlook.Read More>NEO Stock 12 Month Forecast
Average Price Target
$13.19
▲(78.48%Upside)